Polyclonal, polyfunctional multi-antigen HIV-specific T cells (HXTC) derived from
both HIV positive and HIV negative individuals, suppress active HIV replication in
vitro—providing a promising platform for mediating a functional HIV cure in the context
of allogeneic stem cell transplant (SCT). While the inclusion of cytotoxic CD4+ T
cells in T cell products has been shown to enhance in vivo persistence, in the HIV
setting, the risks for infection is a limitation. To address this, we propose providing
resistance to HXTC by using a broadly neutralizing HIV antibody directed against the
X5 portion of HIV envelope. We hypothesized that expression of this protein via a
GPI artificial receptor on HXTC would prevent infection as the GPI (glycosyl-phosphatidylinositol)
signal targets the X5 scFv for expression on lipid rafts, placing it in close proximity
to CD4. Hence, during HIV infection of a CD4 T cell, the X5-GPI AR can potentially
recognize the transiently exposed X5 epitope on gp120 and block the fusion step.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
